Kuwait Life Sciences Company
Kuwait Life Sciences Company (KLSC), established in 2010, operates as a venture capital firm based in Safat, Kuwait. It is fully owned by the National Technology Enterprises Company, which serves as the investment arm of the Kuwait Investment Authority. KLSC specializes in healthcare innovations, targeting unmet needs in the Middle East and North Africa (MENA) region. The company engages in healthcare investments, life sciences training, medical technology, and pharmaceutical distribution. KLSC employs a strategic investment approach that encompasses incubation of local and regional projects, international venture capital investments, and private equity in established companies. It partners with private sector entrepreneurs to foster technology transfer and supports projects that align with regional demands. Noteworthy initiatives developed by KLSC include the Life Sciences Academy and platforms for medical devices and pharmaceuticals. The firm focuses on pre-commercialization stage companies with substantial growth potential, as well as established healthcare firms aiming for regional expansion. By leveraging its expertise, KLSC aims to enhance healthcare services and systems within the MENA region.
Top Stages
4 past transactions
Quanta
Series B in 2014
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
NewBridge Pharmaceuticals
Series C in 2013
NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, established in 2007. The company focuses on addressing unmet medical needs in the Middle East, Africa, Turkey, and Caspian regions through the in-licensing, acquisition, registration, and commercialization of pharmaceuticals, biologics, and medical diagnostics. NewBridge offers a diverse portfolio of products that includes oncology and supportive care medications such as Abstral for cancer pain management, Clasteon for bone metastasis and hypercalcemia, and Sancuso for preventing chemotherapy-induced nausea. Additionally, it provides metabolic care treatments like Gliconorm for diabetes and PYLERA for H. pylori eradication. The company's offerings also extend to CNS care products, including Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care solutions like Cimzia for rheumatoid arthritis. By focusing on therapeutic areas such as oncology, diabetes, and metabolic disorders, NewBridge Pharmaceuticals aims to support patients with critical health challenges in its target regions.
SuperSonic Imagine
Private Equity Round in 2013
SuperSonic Imagine SA is a medical technology company based in Aix-en-Provence, France, specializing in the development and manufacture of ultrasound imaging systems. Founded in 2005, the company is recognized for its Aixplorer system, which delivers high-definition, high-contrast imaging crucial for diagnosing and monitoring various conditions, including breast, prostate, and thyroid cancers, as well as liver diseases. SuperSonic Imagine also offers the ShearWave technology platform, which focuses on quantitative elastography for assessing tissue elasticity. The company operates primarily in France, the United States, and China, and distributes its products through a network of offices and partners across various countries, including Belgium, Germany, and the United Kingdom. As a subsidiary of Hologic Hub Ltd, SuperSonic Imagine continues to innovate in the field of medical imaging technology, enhancing the capabilities of healthcare practitioners.
NewBridge Pharmaceuticals
Series B in 2010
NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, established in 2007. The company focuses on addressing unmet medical needs in the Middle East, Africa, Turkey, and Caspian regions through the in-licensing, acquisition, registration, and commercialization of pharmaceuticals, biologics, and medical diagnostics. NewBridge offers a diverse portfolio of products that includes oncology and supportive care medications such as Abstral for cancer pain management, Clasteon for bone metastasis and hypercalcemia, and Sancuso for preventing chemotherapy-induced nausea. Additionally, it provides metabolic care treatments like Gliconorm for diabetes and PYLERA for H. pylori eradication. The company's offerings also extend to CNS care products, including Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care solutions like Cimzia for rheumatoid arthritis. By focusing on therapeutic areas such as oncology, diabetes, and metabolic disorders, NewBridge Pharmaceuticals aims to support patients with critical health challenges in its target regions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.